Direct vasoactive properties of thienopyridine-derived nitrosothiols

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 5, 2011, Pages 550-558

  Bundhoo, Shantu S ^a   Anderson, Richard A ^a   Sagan, Ewelina ^a   Dada, Jessica ^a   Harris, Rebeca ^a   Halcox, Julian P ^a   Lang, Derek ^a   James, Philip E ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

nitrosothiol; thienopyridine; vessel relaxation

Indexed keywords

CLOPIDOGREL; CLOPIDOGREL NITROSOTHIOL; DRUG METABOLITE; GUANYLATE CYCLASE; NITRITE; PRASUGREL; PRASUGREL NITROSOTHIOL; S NITROSOTHIOL; THIENOPYRIDINE DERIVATIVE; THIOL; TICLOPIDIN; TICLOPIDINE; TICLOPIDINE NITROSOTHIOL; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA CONSTRICTION; AQUEOUS SOLUTION; ARTICLE; CHEMICAL ENVIRONMENT; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG POTENCY; DRUG RELEASE; EXPERIMENTAL RABBIT; MALE; NONHUMAN; PRIORITY JOURNAL; PROPENSITY SCORE; VASCULAR ENDOTHELIUM; VASCULAR RING; VASCULAR TISSUE; VASODILATATION;

ANIMALS; AORTA, THORACIC; GLUTATHIONE; GUANYLATE CYCLASE; HYDROGEN-ION CONCENTRATION; LUMINESCENT MEASUREMENTS; MALE; MASS SPECTROMETRY; MOLECULAR STRUCTURE; NITRO COMPOUNDS; OXADIAZOLES; OZONE; PIPERAZINES; QUINOXALINES; RABBITS; S-NITROSOTHIOLS; SODIUM NITRITE; SPECTROPHOTOMETRY, ULTRAVIOLET; THIENOPYRIDINES; THIOPHENES; TICLOPIDINE; VASODILATION; VASODILATOR AGENTS;

EID: 80955163799     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31822f578c     Document Type: Article

References (56)

1. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108: 1682-1687.
2. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358:527-533.
3. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 1996;93:215-222.
4. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357: 2001-2015.
5. Bennett J, Tully L, Wilds S. Prescribing Points. Oxford: Medicines Management Team, Oxfordshire Primary Care Trust; 2009.
6. Yoneda K, Iwamura R, Kishi H, et al. Identification of the active metabolite of ticlopidine from rat in vitro metabolites. Br J Pharmacol. 2004; 142:551-557.
7. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-99.
8. Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006;34:600-607.
9. Borja Ibanez GV, Badimon JJ. Pharmacology of thienopyridines: rationale for dual pathway inhibition. Eur Heart J Suppl. 2006;8:G3-G9.
10. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007; 153:66 e9-e16.
11. Yang LH, Fareed J. Vasomodulatory action of clopidogrel and ticlopidine. Thromb Res. 1997;86:479-491.
12. Yang LH, Hoppensteadt D, Fareed J. Modulation of vasoconstriction by clopidogrel and ticlopidine. Thromb Res. 1998;92:83-89.
13. Gryglewski RJ, Korbut R, Swies J, et al. Effect of ticlopidine on streptokinaseinduced thrombolysis in rats. Wien Klin Wochenschr. 1999;111:98-102.
14. Gryglewski RJ, Korbut R, Swies J, et al. Thrombolytic action of ticlopidine: possible mechanisms. Eur J Pharmacol. 1996;308:61-67.
15. Ziemianin B, Olszanecki R, Uracz W, et al. Thienopyridines: effects on cultured endothelial cells. J Physiol Pharmacol. 1999;50:597-604.
16. Jakubowski A, Chlopicki S, Olszanecki R, et al. Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart. Prostaglandins Leukot Essent Fatty Acids. 2005;72:139-145.
17. Giachini FR, Osmond DA, Zhang S, et al. Clopidogrel, independent of vascular P2Y12 receptor, improves the arterial function. in small mesenteric arteries from Ang II-hypertensive rats. Clin Sci (Lond). 2009 [Epub ahead of print].
18. Warnholtz A, Ostad MA, Velich N, et al. A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a doubleblind randomized study. Atherosclerosis. 2008;196:689-695.
19. Ignarro LJ, Lippton H, Edwards JC, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther. 1981;218:739-749.
20. Feelisch M, te Poel M, Zamora R, et al. Understanding the controversy over the identity of EDRF. Nature. 1994;368:62-65.
21. Mathews WR, Kerr SW. Biological activity of S-nitrosothiols: the role of nitric oxide. J Pharmacol Exp Ther. 1993;267:1529-1537.
22. Radomski MW, Rees DD, Dutra A, et al. S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol. 1992;107: 745-749.
23. Simon DI, Stamler JS, Jaraki O, et al. Antiplatelet properties of protein Snitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. Arterioscler Thromb. 1993;13:791-799.
24. Merryman PF, Clancy RM, He XY, et al. Modulation of human T cell responses by nitric oxide and its derivative, S-nitrosoglutathione. Arthritis Rheum. 1993;36:1414-1422.
25. Gow A, Doctor A, Mannick J, et al. S-nitrosothiol measurements in biological systems. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:140-151.
26. Hausladen A, Gow AJ, Stamler JS. Nitrosative stress: metabolic pathway involving the flavohemoglobin. Proc Natl Acad Sci U S A. 1998;95: 14100-14105.
27. Gow AJ, Stamler JS. Reactions between nitric oxide and haemoglobin under physiological conditions. Nature. 1998;391:169-173.
28. Jia L, Bonaventura C, Bonaventura J, et al. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature. 1996; 380:221-226.
29. de Belder AJ, MacAllister R, Radomski MW, et al. Effects of S-nitrosoglutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc Res. 1994;28:691-694.
30. James PE, Lang D, Tufnell-Barret T, et al. Vasorelaxation by red blood cells and impairment in diabetes: reduced nitric oxide and oxygen delivery by glycated hemoglobin. Circ Res. 2004;94:976-983.
31. Meyer DJ, Kramer H, Ozer N, et al. Kinetics and equilibria of S-nitrosothiolthiol exchange between glutathione, cysteine, penicillamines and serum albumin. FEBS Lett. 1994;345:177-180.
32. Whiteside WM, Sears DN, Young PR, et al. Properties of selected S-nitrosothiols compared to nitrosylated WR-1065. Radiat Res. 2002; 157:578-588.
33. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrastinduced nephropathy in primary angioplasty. N Engl J Med. 2006;354: 2773-2782.
34. Lauterburg BH, Corcoran GB, Mitchell JR. Mechanism of action of Nacetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest. 1983;71:980-991.
35. Faintuch J, Aguilar PB, Nadalin W. Relevance of N-acetylcysteine in clinical practice: fact, myth or consequence?. Nutrition. 1999;15: 177-179.
36. Chirumamilla R, Marchant R, Nigam P. Captopril and its synthesis from chiral intermediates [review]. J Chem Technol Biotechnol. 2001;76: 123-127.
37. Munthe E, Jellum E, Aaseth J. Some aspects of the mechanism of action of penicillamine in rheumatoid arthritis. Scand J Rheumatol Suppl. 1979; (28):6-12.
38. Jellum E, Aaseth J, Munthe E. Is the mechanism of action during treatment of rheumatoid arthritis with penicillamine and gold thiomalate the same?. Proc R Soc Med. 1977;70(suppl 3):136-139.
39. Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 2004; 92:311-316.
40. Ding Z, Kim S, Dorsam RT, et al. Inactivation of the human P2Y12 receptor by thiol reagent requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood. 2003;101: 3908-3914.
41. Pinder AG, Rogers SC, Khalatbari A, et al. The measurement of nitric oxide and its metabolites in biological samples by ozone-based chemiluminescence. Methods Mol Biol. 2008;476:11-28.
42. Pinder AG, Pittaway E, Morris K, et al. Nitrite directly vasodilates hypoxic vasculature via nitric oxide-dependent and -independent pathways. Br J Pharmacol. 2009;157:1523-1530.
43. Maher AR, Milsom AB, Gunaruwan P, et al. Hypoxic modulation of exogenous nitrite-induced vasodilation in humans. Circulation. 2008; 117:670-677.
44. Anderson RA, Bundhoo SS, Sagan E, et al. Direct vasoactive properties of thienopyridine derived nitrosothiols. J Am Coll Cardiol. 2010;56 B26-B28
45. Diesen DL, Hess DT, Stamler JS. Hypoxic vasodilation by red blood cells: evidence for an s-nitrosothiol-based signal. Circ Res. 2008;103: 545-553.
46. Singh SP, Wishnok JS, Keshive M, et al. The chemistry of the Snitrosoglutathione/ glutathione system. Proc Natl Acad Sci U S A. 1996;93:14428-14433.
47. McKnight GM, Smith LM, Drummond RS, et al. Chemical synthesis of nitric oxide in the stomach from dietary nitrate in humans. Gut. 1997;40: 211-214.
48. Gurbel PA, Lau WC, Tantry US. Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008;51:261-263.
49. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256-260.
50. Fock KM, Ang TL, Bee LC, et al. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?. Clin Pharmacokinet. 2008;47:1-6.
51. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827.
52. Rassaf T, Preik M, Kleinbongard P, et al. Evidence for in vivo transport of bioactive nitric oxide in human plasma. J Clin Invest. 2002;109: 1241-1248.
53. Al-Sa'doni HH, Khan IY, Poston L, et al. A novel family of S-nitrosothiols: chemical synthesis and biological actions. Nitric Oxide. 2000;4:550-560.
54. Hogg N. Biological chemistry and clinical potential of S-nitrosothiols. Free Radic Biol Med. 2000;28:1478-1486.
55. Cooke JP, Andon N, Loscalzo J. S-nitrosocaptopril. II. Effects on vascular reactivity. J Pharmacol Exp Ther. 1989;249:730-734.
56. Shaffer JE, Lee F, Thomson S, et al. The hemodynamic effects of Snitrosocaptopril in anesthetized dogs. J Pharmacol Exp Ther. 1991;256: 704-709.